Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Myeloid 1Lymphoid 1Head & Neck 1Genitourinary 1CNS 1Breast 1

Conditions

Urologic Neoplasms 1Thyroid Neoplasms 1Soft Tissue Neoplasms 1Sarcoma 1Recurrence 1Pharyngeal Neoplasms 1Neurofibromatosis 2 1Neoplasms, Mesothelial 1Neoplasms 1Neoplasm Metastasis 1Mouth Neoplasms 1Lymphangioleiomyomatosis 1Erdheim-Chester Disease 1Endocrine Gland Neoplasms 1Colorectal Neoplasms 1Castleman Disease 1Carcinoma, Transitional Cell 1Breast Neoplasms 1

Interventions

Specimen Handling 8Magnetic Resonance Spectroscopy 7Biopsy 7pembrolizumab 6Doxorubicin 6Cyclophosphamide 6X-Rays 4Radiation 4Phantoms, Imaging 4Radiotherapy 3Nuclear Medicine Department, Hospital 3Irinotecan 3Ifosfamide 3ulixertinib 2tipifarnib 2selpercatinib 2pazopanib 2palbociclib 2liposomal doxorubicin 2ivosidenib 2fludarabine 2ensartinib 2atezolizumab 2Temozolomide 2Surveys and Questionnaires 2Gemcitabine 2Fluorodeoxyglucose F18 2Carboplatin 2Bevacizumab 2trifluridine tipiracil drug combination 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma × Valproic Acid × 30 days × Clear all
NCT01552434 2026-05-15

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

M.D. Anderson Cancer Center

Phase 1 Terminated
154 enrolled
BreastCNSGenitourinaryHead & NeckLymphoidMyeloidSarcoma

Breast Neoplasms, Carcinoma, Transitional Cell, Endocrine Gland Neoplasms, Castleman Disease, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms, Pharyngeal Neoplasms, Recurrence, Sarcoma, Soft Tissue Neoplasms, Thyroid Neoplasms, Urologic Neoplasms, Neurofibromatosis 2, Lymphangioleiomyomatosis, Neoplasms, Mesothelial, Erdheim-Chester Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡